THE BIG NEWS IS MICROSPHERES.
ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) is the first and only FDA-approved treatment for osteoarthritis knee pain to use extended-release microsphere technology.
What’s so special about these microspheres?
They’re tiny particles that are so small, they cannot be seen by the naked eye. They contain a medicine called triamcinolone acetonide, which helps reduce pain and inflammation caused by osteoarthritis.
Once injected directly into the knee, the microspheres stay put, slowly and continually releasing their medicine for about 3 months.
ZILRETTA microspheres stay right in your knee joint—right where the pain is.
After releasing all their medicine into the knee joint, the microspheres break down and turn into carbon dioxide and water, which are naturally found in the body.
ZILRETTA microspheres slowly release pain medication into the knee joint for about 3 months
See how ZILRETTA microsphere technology works
News for people with Type 2 diabetes
In a small clinical trial of people with osteoarthritis of the knee and Type 2 diabetes, minimal elevation in their blood glucose levels were experienced after treatment with ZILRETTA.
Note: This clinical trial only measured blood glucose levels, not the amount of pain relief or safety in patients with Type 2 diabetes.